NDFIP2 Suppresses Colorectal Cancer Metastasis Through DDX3X‐Dependent R‐Loop Remodeling and GNG13 Transcriptional Activation
Advanced Science · 31.10.2026
DOI: 10.1002/advs.78466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 31.10.2026. Verfasst von Enjian Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Everest Program of The Affiliated Hospital of Xuzhou Medical University, National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Distant metastasis remains the leading cause of colorectal cancer (CRC) mortality, yet the underlying molecular mechanisms remain incompletely defined. Integrating RNA sequencing (RNA‐seq) profiling and clinical validation, we identified NDFIP2 as significantly downregulated in metastatic CRC. Functionally, NDFIP2 loss drove epithelial‐mesenchymal transition (EMT), stemness, and metastasis via PI3K/AKT hyperactivation. Mechanistically, NDFIP2 serves as an adaptor recruiting the E3 ligase NEDD4 to induce K48‐linked polyubiquitination and proteasomal degradation of DDX3X. Unrestrained DDX3X resolves R‐loops at the GNG13 promoter and recruits the transcription factor CTCF, synergistically enhancing GNG13 transcription to amplify PI3K/AKT signaling. Targeting this vulnerability, we engineered a cell‐permeable NDFIP2‐derived iRGD‐conjugated peptide (ND‐iRGD). In vivo administration of this construct suppressed DDX3X/GNG13/PI3K/AKT signaling, thereby attenuating distant metastasis and prolonging murine survival. Collectively, NDFIP2 acts as a critical metastasis suppressor via the DDX3X/R‐loop/GNG13 axis, presenting the ND‐iRGD peptide as a promising translatable therapeutic strategy for metastatic CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Jiangsu Key Laboratory of Organ Transplantation and Transplant Immunology, Xuzhou Medical University, Xuzhou, China.
- Technology Innovation and Public Service Center, Huaihai Medical Science and Technology Innovation Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Biology and Biochemistry, Center For Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas, USA.
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Pengbo Zhang, Xin Liu, Yi Zhang
Förderung
- Everest Program of The Affiliated Hospital of Xuzhou Medical University
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Affiliated Hospital of Xuzhou Medical University
Zitieren
APA
Zhang, E., Li, Y., Shu, J., Xu, S., Lv, H., Zhang, C., Zhang, P., Wu, N., Gong, S., Zhang, X., Ren, Z., Liu, X., & Zhang, Y. (2026). NDFIP2 Suppresses Colorectal Cancer Metastasis Through DDX3X‐Dependent R‐Loop Remodeling and GNG13 Transcriptional Activation. Advanced Science. https://doi.org/10.1002/advs.78466
Vancouver
Zhang E, Li Y, Shu J, Xu S, Lv H, Zhang C, et al. NDFIP2 Suppresses Colorectal Cancer Metastasis Through DDX3X‐Dependent R‐Loop Remodeling and GNG13 Transcriptional Activation. Advanced Science. 2026. doi:10.1002/advs.78466
BibTeX
@article{Zhang2026,
author = {Zhang, Enjian and Li, Yanfang and Shu, Jiaxin and Xu, Shang and Lv, Heng and Zhang, Chong and Zhang, Pengbo and Wu, Nai and Gong, Shuai and Zhang, Xiuzhong and Ren, Zeqiang and Liu, Xin and Zhang, Yi},
title = {NDFIP2 Suppresses Colorectal Cancer Metastasis Through DDX3X‐Dependent R‐Loop Remodeling and GNG13 Transcriptional Activation},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78466}
}
EUVIMED